Login Register Cart 0
Generic placeholder image

Current HIV Research

Editor-in-Chief

ISSN (Print): 1570-162X
ISSN (Online): 1873-4251

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Impact of Metabolic Syndrome and Cardiovascular Risk on the Quality of Life of People Living with HIV

Author(s): Ítalo Inácio Pereira, Adrielly Katrine Tozetto Morais Muto, Regyane Ferreira Guimarães Dias, Hélio Ranes de Menezes Filho, Eduardo Vignoto Fernandes, Luiz Fernando Gouvêa-e-Silva* and Ludimila Paula Vaz Cardoso

Volume 22, Issue 3, 2024

Published on: 14 May, 2024

Page: [170 - 180] Pages: 11

DOI: 10.2174/011570162X299815240507070904

Price: $65

Abstract

Background: The time elapsed since HIV infection diagnosis (TdiagHIV) affects the quality of life (QoL) and can get worse when chronic illnesses start.

Objective: The aim of this study was to analyze the impact of metabolic syndrome (MetS) and cardiovascular risk (CVR) on the QoL of people living with HIV (PLHIV).

Methods: Cross-sectional study, with 60 PLHIV followed at a Reference Center in the city of Jataí, Goiás, Brazil. Data collection involved sociodemographic, clinical, CVR, MetS, and QoL information. The data were analyzed using descriptive and inferential statistics, with the BioEstat 5.3 program adopting p<0.05.

Results: There was a predominance of men (61.7%), aged ≤38 years (53.3%), with a TdiagHIV of 97.88±85.65 months and use of antiretroviral therapy (ART) of 80.13±69.37 months. The worst domain of QoL was concern about confidentiality (40 points), and the best was medication concerns (95 points). MetS predominated at 18.3% and a moderate CVR at 11.7%. MetS was positively associated with age >38 years, the female sex, with the lowest score in QoL for general function, and the highest for TdiagHIV and the use of ART (p<0.05). A moderate CRV was positively related to higher TdiagHIV and ART use, and low HDL-c, and the lowest score for QoL was found for trust in a professional (p<0.05).

Conclusion: PLHIV who are older, have a higher TdiagHIV, and use ART are more likely to develop MetS and moderate CVR. The presence of these diseases in PLHIV causes impairment in areas of QoL.

« Previous Next »
Graphical Abstract

[1]
Ministry of Health. HIV/Aids epidemiological bulletin. Brasilia 2022. Available from: https://www.gov.br/aids/pt-br/centrais-de-conteudo/boletins-epidemiologicos/2022/hiv-aids
[2]
Paula AA, Pires DF, Alves Filho P, et al. Mortality profiles among people living with HIV/AIDS: comparison between Rio de Janeiro and other federative units between 1999 and 2015. Rev Bras Epidemiol 2020; 23: e200017.
[http://dx.doi.org/10.1590/1980-549720200017] [PMID: 32215542]
[3]
World Health Statistics. World Health Organization: Geneva, Switzerland. 2021. Available from: https://www.who.int/data/gho/publications/world-health-statistics
[4]
Aberg JA. Aging and HIV infection: Focus on cardiovascular disease risk. Top Antivir Med 2020; 27(4): 102-5.
[PMID: 32224501]
[5]
Nguyen KA, Peer N, Mills EJ, Kengne AP. A Meta-analysis of the metabolic syndrome prevalence in the global HIV-infected population. PLoS One 2016; 11(3): e0150970.
[http://dx.doi.org/10.1371/journal.pone.0150970] [PMID: 27008536]
[6]
Chatzinikolaou A, Tzikas S, Lavdaniti M. Assessment of quality of life in patients with cardiovascular disease using the SF-36, MacNew, and EQ-5D-5L questionnaires. Cureus 2021; 13(9): e17982.
[http://dx.doi.org/10.7759/cureus.17982] [PMID: 34667665]
[7]
Lin YH, Chang HT, Tseng YH, et al. Changes in metabolic syndrome affect the health-related quality of life of community-dwelling adults. Sci Rep 2021; 11(1): 20267.
[http://dx.doi.org/10.1038/s41598-021-99767-y] [PMID: 34642379]
[8]
Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome. Circulation 2005; 112(17): 2735-52.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.105.169404] [PMID: 16157765]
[9]
Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity 2011. Available from: https://apps.who.int/iris/handle/10665/85839
[10]
Segatto AFM, Freitas Junior IF, Santos VR, et al. Lipodystrophy in HIV/AIDS patients with different levels of physical activity while on antiretroviral therapy. Rev Soc Bras Med Trop 2011; 44(4): 420-4.
[http://dx.doi.org/10.1590/S0037-86822011000400004] [PMID: 21860886]
[11]
Obesity: preventing and manging the global epidemic report of a WHO consultation on obesity Geneva, Switzerland, 2000. Available from: https://apps.who.int/iris/handle/10665/42330
[12]
Scherzer R, Heymsfield SB, Lee D, et al. Decreased limb muscle and increased central adiposity are associated with 5-year allcause mortality in HIV infection. AIDS 2011; 25(11): 1405-14.
[http://dx.doi.org/10.1097/QAD.0b013e32834884e6] [PMID: 21572308]
[13]
Craig CL, Marshall AL, Sjöström M, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 2003; 35(8): 1381-95.
[http://dx.doi.org/10.1249/01.MSS.0000078924.61453.FB] [PMID: 12900694]
[14]
Physical activity guidelines for the brazilian population. Ministry of Health of Brazil 2021; 54. Available from: https://aps.saude.gov.br/biblioteca/visualizar/MjA1Mg==
[15]
Holmes WC, Shea JA. A new HIV/AIDS-targeted quality of life (HAT-QoL) instrument: Development, reliability, and validity. Med Care 1998; 36(2): 138-54.
[http://dx.doi.org/10.1097/00005650-199802000-00004] [PMID: 9475469]
[16]
De Soárez PC, Castelo A, Abrão P, Holmes WC, Ciconelli RM. Translation and validation of an AIDS quality of life assessment questionnaire in Brazil. Rev Panam Salud Publica 2009; 25(1): 69-76.
[http://dx.doi.org/10.1590/S1020-49892009000100011] [PMID: 19341527]
[17]
Sposito AC, Caramelli B, Fonseca FAH, et al. IV Brazilian guideline on dyslipidemia and prevention of atherosclerosis: Department of atherosclerosis of the brazilian society of cardiology. Arq Bras Cardiol 2007; 88 (Suppl. 1): 2-19.
[http://dx.doi.org/10.1590/S0066-782X2007000700002] [PMID: 17515982]
[18]
Caixeta AKS, Souza LSM, Fernandes EV, Dias RFG, Menezes Filho HR, Gouvêa-e-Silva LF. People living with HIV/AIDS in southwest Goiás: Sociodemographic, clinical and laboratory characterization in the year 2018. Rev Med 2023; 102(1): e195987.
[http://dx.doi.org/10.11606/issn.1679-9836.v102i1e-195987]
[19]
Watanabe BT, Araújo IB, Menezes Filho HR, Oliveira DM, Fernandes EV, Gouvêa-e-Silva LF. Health condition of HIV patients: Evaluation of metabolic syndrome and cardiovascular risk. J Health Sci 2022; 24(4): 277-82.
[http://dx.doi.org/10.17921/2447-8938.2022v24n4p277-282]
[20]
Soares GB, Garbin CAS, Rovida TAS, Garbin AJÍ. Quality of life of people living with HIV/AIDS treated by the specialized service in Vitória-ES, Brazil. Cien Saude Colet 2015; 20(4): 1075-84.
[http://dx.doi.org/10.1590/1413-81232015204.00522014] [PMID: 25923619]
[21]
Pimentel GS, Ceccato MDGB, Costa JO, Mendes JC, Bonolo PF, Silveira MR. Quality of life in individuals initiating antiretroviral therapy: A cohort study. Rev Saude Publica 2020; 54: 146.
[http://dx.doi.org/10.11606/s1518-8787.2020054001920] [PMID: 33331489]
[22]
Santos VF, Galvão MT, Cunha GH, Lima ICV, Gir E. Alcohol effect on HIV-positive individuals: Treatment and quality of life. Acta Paul Enferm 2017; 30(1): 94-100.
[http://dx.doi.org/10.1590/1982-0194201700014]
[23]
Schwitters A, Sabatier J, Seth P, et al. HIV and alcohol knowledge, self-perceived risk for HIV, and risky sexual behavior among young HIV-negative men identified as harmful or hazardous drinkers in Katutura, Namibia. BMC Public Health 2015; 15(1): 1182.
[http://dx.doi.org/10.1186/s12889-015-2516-5] [PMID: 26607874]
[24]
Ministry of Health. Clinical Protocol and Therapeutic Guidelines for the Management of HIV Infection in Adults. Brasília: Ministry of Health. 2018. Available from: https://www.gov.br/aids/pt-br/centrais-de-conteudo/pcdts/2013/hiv-aids/pcdt_manejo_adulto_12_2018_web.pdf/view
[25]
Cioe PA, Crawford SL, Stein MD. Cardiovascular risk-factor knowledge and risk perception among HIV-infected adults. J Assoc Nurses AIDS Care 2014; 25(1): 60-9.
[http://dx.doi.org/10.1016/j.jana.2013.07.006] [PMID: 24070645]
[26]
Ferrari TK, Cesar CLG, Alves MCGP, Barros MBA, Goldbaum M, Fisberg RM. Healthy lifestyle in São Paulo, Brazil. Cad Saude Publica 2017; 33(1): e00188015.
[http://dx.doi.org/10.1590/0102-311x00188015] [PMID: 28125129]
[27]
Masenga SK, Elijovich F, Koethe JR, et al. Hypertension and metabolic syndrome in persons with HIV. Curr Hypertens Rep 2020; 22(10): 78.
[http://dx.doi.org/10.1007/s11906-020-01089-3] [PMID: 32880756]
[28]
Dinh DM, Volpe GE, Duffalo C, et al. Intestinal microbiota, microbial translocation, and systemic inflammation in chronic HIV infection. J Infect Dis 2015; 211(1): 19-27.
[http://dx.doi.org/10.1093/infdis/jiu409] [PMID: 25057045]
[29]
Pinto-Cardoso S, Klatt NR, Reyes-Terán G. Impact of antiretroviral drugs on the microbiome. Curr Opin HIV AIDS 2018; 13(1): 53-60.
[http://dx.doi.org/10.1097/COH.0000000000000428] [PMID: 29028667]
[30]
Gouvêa-e-Silva LF, Silva CF, Araujo IB, Lima VS, Fernandes EV, Xavier MB. Relationship between handgrip strength and age in the body composition variables among people living with HIV. Curr HIV Res 2022; 20(6): 472-8.
[http://dx.doi.org/10.2174/1570162X20666220927114848] [PMID: 36173077]
[31]
Costa CRB, Melo ES, Antonini M, Pontes PS, Gir E, Reis RK. Overweight and obesity in people living with HIV. Rev Gaúcha Enferm 2021; 42: e20200310.
[http://dx.doi.org/10.1590/1983-1447.2021.20200310]
[32]
Vargas-Pacherrez D, Cotrim HP, Pires L, et al. Metabolic syndrome in HIV-patients in antiretroviral therapy. Curr HIV Res 2020; 18(6): 388-95.
[http://dx.doi.org/10.2174/1570162X18666200609115615] [PMID: 32516101]
[33]
Leal JA, Fausto MA, Carneiro M. Anthropometric risk factors for metabolic syndrome in HIV patients. MedicalExpress 2016; 3(4): M160405.
[http://dx.doi.org/10.5935/MedicalExpress.2016.04.05]
[34]
Raposo MA, Armiliato GNA, Guimarães NS, Caram CA, Silveira RDS, Tupinambás U. Metabolic disorders and cardiovascular risk in people living with HIV/AIDS without the use of antiretroviral therapy. Rev Soc Bras Med Trop 2017; 50(5): 598-606.
[http://dx.doi.org/10.1590/0037-8682-0258-2017] [PMID: 29160505]
[35]
Falcão MC, Zírpoli JC, Albuquerque VMD, et al. Association of biomarkers with atherosclerosis and risk for coronary artery disease in patients with HIV. Arq Bras Cardiol 2012; 99(5): 971-8.
[http://dx.doi.org/10.1590/S0066-782X2012005000093] [PMID: 23080223]
[36]
Silva EFR, Bassichetto KC, Lewi DS. Lipid profile, cardiovascular risk factors and metabolic syndrome in a group of AIDS patients. Arq Bras Cardiol 2009; 93(2): 113-8.
[http://dx.doi.org/10.1590/S0066-782X2009000800008] [PMID: 19838487]
[37]
Costa CRB, Melo ES, Antonini M, et al. Association between sociodemographic and behavioral factors with metabolic syndrome in people living with HIV. Rev Gaúcha Enferm 2019; 40: e20180379.
[http://dx.doi.org/10.1590/1983-1447.2019.20180379] [PMID: 31188990]
[38]
Krishnan S, Schouten JT, Atkinson B, et al. Metabolic syndrome before and after initiation of antiretroviral therapy in treatment-naive HIV-infected individuals. J Acquir Immune Defic Syndr 2012; 61(3): 381-9.
[http://dx.doi.org/10.1097/QAI.0b013e3182690e3c] [PMID: 22828718]
[39]
Krishnan S, Schouten JT, Atkinson B, et al. Changes in metabolic syndrome status after initiation of antiretroviral therapy. J Acquir Immune Defic Syndr 2015; 68(1): 73-80.
[http://dx.doi.org/10.1097/QAI.0000000000000397] [PMID: 25321179]
[40]
d’Arminio Monforte A, Diaz-Cuervo H, De Luca A, et al. Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian cohort of individuals, naïve for antiretrovirals (ICONA) foundation study cohort in the period 2004–2014. HIV Med 2019; 20(2): 99-109.
[http://dx.doi.org/10.1111/hiv.12683] [PMID: 30461158]
[41]
Pereira II, Muto AKTM, Brito ER, Silva ML, Cardoso L, Gouvêa-e-Silva LF. Relationship between metabolic syndrome and cardiovascular risk with quality of life in people living with HIV: An integrative review. Rev Med 2023; 102(5): e-209249.
[http://dx.doi.org/10.11606/issn.1679-9836.v102i5e-209249]
[42]
Oliveira JS, Lima FLA, Saldanha AAW. Quality of life in HIV+ people over 50 years of age: A comparative study with the general population. STD - J Bras Diseases Sex Transm 2008; 20(3-4): 179-84.
[43]
Martins Neto C, Pires EMC, Brito CS, et al. Quality of life in the context of patients with HIV/AIDS: A comparative study. Saúde Pesqui 2019; 12(2): 333-41.
[http://dx.doi.org/10.17765/2176-9206.2019v12n2p333-341]
[44]
Gouvêa-e-Silva LF, Lima CNS, Fernandes KTL, Takanashi SYL, Xavier MB. Quality of life and handgrip strength of HIV patients diagnosed with neurotoxoplasmosis. Rev Bras Cineantropom Desempenho Hum 2019; 21: e59185.
[http://dx.doi.org/10.1590/1980-0037.2019v21e59185]
[45]
Primeira MR, Santos WM, Paula CC, Padoin SMM. Quality of life, adherence and clinical indicators among people living with HIV. Acta Paul Enferm 2020; 33: eAPE20190141.
[http://dx.doi.org/10.37689/acta-ape/2020AO0141]
[46]
Andersson GZ, Reinius M, Eriksson LE, et al. Stigma reduction interventions in people living with HIV to improve health-related quality of life. Lancet HIV 2020; 7(2): e129-40.
[http://dx.doi.org/10.1016/S2352-3018(19)30343-1] [PMID: 31776098]
[47]
Kanters S, Vitoria M, Zoratti M, et al. Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400 mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis. EClinicalMedicine 2020; 28: 100573.
[http://dx.doi.org/10.1016/j.eclinm.2020.100573] [PMID: 33294805]
[48]
Neves JK, Cavalcante CM, Barros RJS, Magalhães MGPA, Souza ES. Atazanavir/ritonavir vs Efavirenz as the first line of treatment in adults living with HIV. Rev Med 2021; 100(1): 28-34.
[http://dx.doi.org/10.11606/issn.1679-9836.v100i1p28-34]
[49]
De Socio GV, Pucci G, Baldelli F, Schillaci G. Observed versus predicted cardiovascular events and all-cause death in HIV infection: A longitudinal cohort study. BMC Infect Dis 2017; 17(1): 414.
[http://dx.doi.org/10.1186/s12879-017-2510-x] [PMID: 28606059]
[50]
Beraldo RA, Santos APD, Guimarães MP, et al. Body fat redistribution and changes in lipid and glucose metabolism in people living with HIV/AIDS. Rev Bras Epidemiol 2017; 20(3): 526-36.
[http://dx.doi.org/10.1590/1980-5497201700030014] [PMID: 29160443]
[51]
Alvarez C, Salazar R, Galindez J, et al. Metabolic syndrome in HIV-infected patients receiving antiretroviral therapy in Latin America. Braz J Infect Dis 2010; 14(3): 256-63.
[http://dx.doi.org/10.1016/S1413-8670(10)70053-2] [PMID: 20835509]
[52]
Freitas RS, Santos IS, Matos SMA, Aquino EML, Amorim LDAF. Ideal cardiovascular health at ELSA-Brasil: Non-additivity effects of gender, race, and schooling by using additive and multiplicative interactions. Cad Saude Publica 2022; 38(8): e00266221.
[http://dx.doi.org/10.1590/0102-311xen266221] [PMID: 35946616]
[53]
de Visser CL, Bilo HJG, Groenier KH, de Visser W, Meyboom-de Jong B. The influence of cardiovascular disease on quality of life in type 2 diabetics. Qual Life Res 2002; 11(3): 249-61.
[http://dx.doi.org/10.1023/A:1015287825660] [PMID: 12074262]
[54]
Ko HY, Lee JK, Shin JY, Jo E. Health-related quality of life and cardiovascular disease risk in Korean adults. Korean J Fam Med 2015; 36(6): 349-56.
[http://dx.doi.org/10.4082/kjfm.2015.36.6.349] [PMID: 26634104]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy